BACKGROUND: Obesity and diabetes mellitus are associated with an increased risk of pancreatic cancer. These associations may be secondary to consequences of peripheral insulin resistance, pancreatic β-cell dysfunction, or hyperglycemia itself. Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic β-cell dysfunction. METHODS: This was a prospective, nested case-control study of 449 case patients and 982 control subjects with prediagnostic blood samples and no diabetes history from five prospective US cohorts followed through 2008. Two or three control subjects were matched to each case patient by year of birth, cohort, smoking, and fasting status. Pancreatic cancer risk was assessed by prediagnostic HbA1c, insulin, proinsulin, and proinsulin to insulin ratio with multivariable-adjusted logistic regression. All P values were two-sided. RESULTS: The highest vs lowest quintiles of HbA1c, insulin, and proinsulin were associated with with an increased risk for pancreatic cancer (odds ratio [OR] = 1.79; 95% confidence interval [CI] = 1.17 to 2.72, P trend = .04 for HbA1c; OR = 1.57; 95% CI = 1.08 to 2.30; Ptrend = .002 for insulin; and OR = 2.22; 95% CI = 1.50 to 3.29; P trend < .001 for proinsulin). Proinsulin to insulin ratio was not associated with pancreatic cancer risk. Results were similar across studies (all P heterogeneity > .29). In cancers developing 10 or more years after blood collection, the associations with insulin and proinsulin became stronger (highest vs lowest quintile, OR = 2.77; 95% CI = 1.28 to 5.99 for insulin and OR = 3.60; 95% CI = 1.68 to 7.72 for proinsulin). In mutually adjusted models including HbA1c, insulin, and proinsulin, only proinsulin remained statistically significant ( highest vs lowest quintile, OR = 2.55; 95% CI = 1.54 to 4.21; Ptrend < .001). CONCLUSIONS: Among participants from five large prospective cohorts, circulating markers of peripheral insulin resistance, rather than hyperglycemia or pancreatic β-cell dysfunction, were independently associated with pancreatic cancer risk.
BACKGROUND: Obesity and diabetes mellitus are associated with an increased risk of pancreatic cancer. These associations may be secondary to consequences of peripheral insulin resistance, pancreatic β-cell dysfunction, or hyperglycemia itself. Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic β-cell dysfunction. METHODS: This was a prospective, nested case-control study of 449 case patients and 982 control subjects with prediagnostic blood samples and no diabetes history from five prospective US cohorts followed through 2008. Two or three control subjects were matched to each case patient by year of birth, cohort, smoking, and fasting status. Pancreatic cancer risk was assessed by prediagnostic HbA1c, insulin, proinsulin, and proinsulin to insulin ratio with multivariable-adjusted logistic regression. All P values were two-sided. RESULTS: The highest vs lowest quintiles of HbA1c, insulin, and proinsulin were associated with with an increased risk for pancreatic cancer (odds ratio [OR] = 1.79; 95% confidence interval [CI] = 1.17 to 2.72, P trend = .04 for HbA1c; OR = 1.57; 95% CI = 1.08 to 2.30; Ptrend = .002 for insulin; and OR = 2.22; 95% CI = 1.50 to 3.29; P trend < .001 for proinsulin). Proinsulin to insulin ratio was not associated with pancreatic cancer risk. Results were similar across studies (all P heterogeneity > .29). In cancers developing 10 or more years after blood collection, the associations with insulin and proinsulin became stronger (highest vs lowest quintile, OR = 2.77; 95% CI = 1.28 to 5.99 for insulin and OR = 3.60; 95% CI = 1.68 to 7.72 for proinsulin). In mutually adjusted models including HbA1c, insulin, and proinsulin, only proinsulin remained statistically significant ( highest vs lowest quintile, OR = 2.55; 95% CI = 1.54 to 4.21; Ptrend < .001). CONCLUSIONS: Among participants from five large prospective cohorts, circulating markers of peripheral insulin resistance, rather than hyperglycemia or pancreatic β-cell dysfunction, were independently associated with pancreatic cancer risk.
Authors: Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Andreas Pfützner; Eberhard Standl; Cloth Hohberg; Thomas Konrad; Hermann-Josef Strotmann; Georg Lübben; Matthias R Langenfeld; Jan Schulze; Thomas Forst Journal: Diabetes Technol Ther Date: 2005-06 Impact factor: 6.118
Authors: Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Rachael Z Stolzenberg-Solomon; Barry I Graubard; Suresh Chari; Paul Limburg; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: JAMA Date: 2005-12-14 Impact factor: 56.272
Authors: Dominique S Michaud; Brian Wolpin; Ed Giovannucci; Simin Liu; Barbara Cochrane; JoAnn E Manson; Michael N Pollak; Jing Ma; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-09-28 Impact factor: 4.254
Authors: Donghui Li; Jeffrey S Morris; Jun Liu; Manal M Hassan; R Sue Day; Melissa L Bondy; James L Abbruzzese Journal: JAMA Date: 2009-06-24 Impact factor: 56.272
Authors: B M Wolpin; D S Michaud; E L Giovannucci; E S Schernhammer; M J Stampfer; J E Manson; B B Cochrane; T E Rohan; J Ma; M N Pollak; C S Fuchs Journal: Br J Cancer Date: 2007-05-29 Impact factor: 7.640
Authors: Brian M Wolpin; Peter Kraft; Jihye Kim; Chen Yuan; Ana Babic; Ying Bao; Clary B Clish; Michael N Pollak; Laufey T Amundadottir; Alison P Klein; Rachael Z Stolzenberg-Solomon; Pari V Pandharipande; Lauren K Brais; Marisa W Welch; Kimmie Ng; Edward L Giovannucci; Howard D Sesso; JoAnn E Manson; Meir J Stampfer; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-22 Impact factor: 4.254
Authors: Leticia M Nogueira; Christina C Newton; Michael Pollak; Debra T Silverman; Demetrius Albanes; Satu Männistö; Stephanie J Weinstein; Eric J Jacobs; Rachael Z Stolzenberg-Solomon Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-17 Impact factor: 4.254
Authors: Brenda M Birmann; Mollie E Barnard; Kimberly A Bertrand; Ying Bao; Marta Crous-Bou; Brian M Wolpin; Immaculata De Vivo; Shelley S Tworoger Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308